Keratitis - Pipeline Review, H2 2017

  • ID: 4419042
  • Report
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Editas Medicine Inc
  • MimeTech Srl
  • NanoViricides Inc
  • SIFI SpA
  • The Medicines Company
  • MORE
Keratitis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2017, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Editas Medicine Inc
  • MimeTech Srl
  • NanoViricides Inc
  • SIFI SpA
  • The Medicines Company
  • MORE
Introduction

Keratitis - Overview

Keratitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Keratitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Keratitis - Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corp

Editas Medicine Inc

EyeGate Pharmaceuticals Inc

MimeTech Srl

NanoViricides Inc

RegeneRx Biopharmaceuticals Inc

SIFI SpA

The Medicines Company

Keratitis - Drug Profiles

acyclovir sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-2088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-31G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IVMED-90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-55933 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIM-45 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polihexanide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-259 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tigecycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBP-245 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-9445 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keratitis - Dormant Projects

Keratitis - Discontinued Products

Keratitis - Product Development Milestones

Featured News & Press Releases

Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease

Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday

Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials

Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259

Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Keratitis, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Keratitis - Pipeline by Adamis Pharmaceuticals Corp, H2

Keratitis - Pipeline by Editas Medicine Inc, H2

Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2

Keratitis - Pipeline by MimeTech Srl, H2

Keratitis - Pipeline by NanoViricides Inc, H2

Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2

Keratitis - Pipeline by SIFI SpA, H2

Keratitis - Pipeline by The Medicines Company, H2

Keratitis - Dormant Projects, H2

Keratitis - Discontinued Products, H2

List of Figures

Number of Products under Development for Keratitis, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adamis Pharmaceuticals Corp
  • Editas Medicine Inc
  • EyeGate Pharmaceuticals Inc
  • MimeTech Srl
  • NanoViricides Inc
  • RegeneRx Biopharmaceuticals Inc
  • SIFI SpA
  • The Medicines Company
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll